Sanofi raises sales guidance driven by Dupixent performance

Sanofi has increased its sales forecasts, citing strong performance from its flagship drug Dupixent. The company maintains its strategic focus on immunology, rare diseases, and vaccines while signaling an intent to pursue growth through targeted acquisitions under new leadership.